Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib


1 Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey
2 Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey
3 Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Tokat, Turkey
4 Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey
5 Department of Internal Medicine, Division of Medical Oncology, Dr. A. Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey
6 Department of Internal Medicine, Division of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey

Correspondence Address:
Bulent Cetin,
Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Suleyman Demirel Univesity, Isparta 32260
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_372_18

Objective: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival. Materials and Methods: The expression of ezrin was measured by immunohistochemistry in 80 patients with ccRCC treated by first-line sunitinib between January 2007 and June 2012. Kaplan–Meier curves and log-rank tests were used for analysis of progression-free survival and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on the survival. Results: In multivariate analysis, liver metastasis (P = 0.018; hazard ratio [HR]: 3.707 (1.257–10.931) and overexpression of ezrin (P = 0.006; HR: 2.993 (1.373–6.523 95% confidence interval) were remained significant factors influencing OS. Overexpression of ezrin in the patients who had progressed in the first 3 months was higher than in the patients who had progressed after 3 months (P = 0.003). The median OS was longer in patients with low levels of ezrin expression (27 months) compared to patients overexpressing ezrin (12 months) (P = 0.001). Conclusion: This is the first study in the literature showing that ezrin status is related with prognosis in patients with metastatic ccRCC.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Cetin B
    -  Gonul II
    -  Gumusay O
    -  Afsar B
    -  Bilgetekin I
    -  Ozet A
    -  Uner A
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed54    
    PDF Downloaded5    

Recommend this journal